Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial. (16th November 2020)

• Record Type: Journal Article
• Authors: Hormoznejad, Razie; Mohammad Shahi, Majid; Rahim, Fakher; Helli, Bijan; Alavinejad, Pezhman; Sharhani, Asaad
• Is Part Of: International journal of food sciences and nutrition. Volume 71:Number 8(2020)
• Page Start: 991
• Page End: 1000
• Publication Date: 2020-11-16
• Subjects: Cranberry -- non-alcoholic fatty liver disease -- clinical trial; Food -- Analysis -- Periodicals; Nutrition -- Periodicals; 641.3
• DOI: 10.1080/09637486.2020.1746957
• Languages: English
• ISSNs: 0963-7486

Abstract

Abstract: A double-blind placebo-controlled randomised clinical trial was conducted on 41 patients with non-alcoholic fatty liver disease (NAFLD). Participants were randomly allocated to receive either a cranberry supplement or a placebo for 12 weeks. Both groups were assigned to follow a weight loss diet. At the end of the study, alanine aminotransferase and insulin decreased significantly in both groups ( p < .05); however, this reduction was significantly greater in the cranberry group than in the placebo group ( p < .05). Significant improvements in insulin resistance were observed in the cranberry group and between the two groups ( p < .001 and p = .020, respectively). Also, there was an improvement in steatosis grade and anthropometric measurements in both groups ( p < .05), and there was no significant difference between the two groups in regard to these factors ( p > .05). It seems that 288 mg of cranberry extract might improve managing NAFLD, which is equivalent to 26 g of dried cranberry.